Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to Post Q1 2025 Earnings of ($0.69) Per Share, HC Wainwright Forecasts

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - HC Wainwright issued their Q1 2025 earnings per share estimates for Protagonist Therapeutics in a research report issued on Thursday, May 9th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of ($0.69) per share for the quarter. HC Wainwright has a "Buy" rating and a $38.00 price objective on the stock. The consensus estimate for Protagonist Therapeutics' current full-year earnings is $1.18 per share. HC Wainwright also issued estimates for Protagonist Therapeutics' Q2 2025 earnings at $2.09 EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at $0.88 EPS and FY2028 earnings at $2.85 EPS.

PTGX has been the topic of several other reports. JPMorgan Chase & Co. boosted their price objective on Protagonist Therapeutics from $34.00 to $37.00 and gave the company an "overweight" rating in a research report on Wednesday, February 28th. StockNews.com upgraded Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, February 28th. Finally, JMP Securities boosted their price objective on Protagonist Therapeutics from $42.00 to $45.00 and gave the company a "market outperform" rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $38.00.

Protagonist Therapeutics Stock Performance

Shares of Protagonist Therapeutics stock traded down $0.04 during trading hours on Friday, hitting $28.23. The company's stock had a trading volume of 513,289 shares, compared to its average volume of 674,190. The business has a 50 day moving average price of $27.77 and a two-hundred day moving average price of $24.02. Protagonist Therapeutics has a 12-month low of $13.72 and a 12-month high of $33.34. The company has a market cap of $1.66 billion, a PE ratio of 11.57 and a beta of 2.09.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.39. The company had revenue of $60.00 million for the quarter, compared to the consensus estimate of $60.00 million.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Protagonist Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company's stock worth $92,373,000 after purchasing an additional 39,055 shares in the last quarter. ProShare Advisors LLC grew its stake in Protagonist Therapeutics by 9.2% in the first quarter. ProShare Advisors LLC now owns 14,345 shares of the company's stock worth $415,000 after purchasing an additional 1,206 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Protagonist Therapeutics in the first quarter worth approximately $35,000. Sei Investments Co. grew its stake in Protagonist Therapeutics by 12.2% in the first quarter. Sei Investments Co. now owns 41,758 shares of the company's stock worth $1,208,000 after purchasing an additional 4,529 shares in the last quarter. Finally, GSA Capital Partners LLP grew its stake in Protagonist Therapeutics by 179.8% in the first quarter. GSA Capital Partners LLP now owns 55,359 shares of the company's stock worth $1,602,000 after purchasing an additional 35,571 shares in the last quarter. Institutional investors own 98.63% of the company's stock.

Insider Buying and Selling

In related news, CFO Asif Ali sold 1,234 shares of the business's stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $25.11, for a total value of $30,985.74. Following the sale, the chief financial officer now directly owns 37,163 shares in the company, valued at $933,162.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 25,000 shares of the business's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $28.31, for a total transaction of $707,750.00. Following the sale, the chief executive officer now directly owns 549,590 shares of the company's stock, valued at $15,558,892.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Asif Ali sold 1,234 shares of the company's stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $25.11, for a total value of $30,985.74. Following the transaction, the chief financial officer now directly owns 37,163 shares in the company, valued at approximately $933,162.93. The disclosure for this sale can be found here. Over the last three months, insiders have sold 83,457 shares of company stock worth $2,553,328. Corporate insiders own 5.00% of the company's stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.